| アブストラクト | BACKGROUND: Andexanet alfa, a Food and Drug Administration (FDA)-approved antidote for apixaban and rivaroxaban, is used to manage life-threatening or uncontrolled bleeding. In patients undergoing cardiopulmonary bypass (CPB), preoperative exposure to andexanet can cause severe heparin resistance, necessitating effective mitigation strategies. A comprehensive review of such strategies remains lacking. OBJECTIVES: This study aimed to systematically review and characterize cases of andexanet-induced heparin resistance in patients undergoing CPB and to evaluate management strategies. METHODS: A systematic search was conducted across multiple databases via the Ovid interface, Cochrane Central Register of Controlled Trials, and the FDA Adverse Event Reporting System. Quality appraisal was performed using a validated instrument for case reports and series describing drug-induced adverse events. RESULTS: Fourteen discrete patient cases met inclusion criteria. After andexanet administration, the mean initial activated clotting time (ACT) was 199.5 seconds, falling short of a target of >/=400 seconds despite additional heparin dosing (mean total, 1123 U/kg). Moreover, 35.7% of all cases involved thrombus formation in the reservoir, 2 of which required a circuit replacement. Antithrombin (AT) concentrate was administered to 75% of those received an adjunct therapy. A prophylactic AT use (mean, 49.9 IU/kg) resulted in an ACT over 400 seconds, while its effects in low dose after the occurrence of thrombosis varied on ACT values. Nafamostat mesylate was used in some cases reported from Japan. CONCLUSION: Heparin resistance following andexanet exposure poses significant procoagulant risk during CPB. Pre-emptive high-dose AT therapy may improve ACT values. Further studies are needed to understand the mechanisms and optimize management of this condition. |
|---|
| ジャーナル名 | Journal of thrombosis and haemostasis : JTH |
|---|
| Pubmed追加日 | 2025/2/8 |
|---|
| 投稿者 | Mishima, Yuko; Townsend, Grace; Clifton, Shari C; Butt, Amir L; Vandyck, Kofi B; Stewart, Kenneth E; Boylan, Paul M; Tanaka, Kenichi A |
|---|
| 組織名 | Department of Anesthesiology, University of Oklahoma Health Sciences Center,;Oklahoma City, Oklahoma, USA.;Reference and Instructional Services, Robert M. Bird Health Sciences Library,;University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.;Oklahoma City, Oklahoma, USA; Department of Surgery, University of Oklahoma;Health Sciences Center, Oklahoma City, Oklahoma, USA.;College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma;City, Oklahoma, USA.;Oklahoma City, Oklahoma, USA. Electronic address: kenichi-tanaka@ouhsc.edu. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39920998/ |
|---|
